ANGPT2 and melanoma: Assuming that an increased Ang-2 and VEGF expression may change the local perivascular microenvironment towards a supporting pre-metastatic environment at the early stages of the metastatic cascade, we further tested whether combined treatment with AMG 38626 (a peptibody binding to angiopoietin-1 and angiopoietin-2) and aflibercept27,28 (a fusion protein containing domains of VEGFR1 and VEGFR2, thereby acting as “VEGF Trap”) at early stages may inhibit melanoma and breast carcinoma BM formation.